Literature DB >> 3282532

Time course of the effects of epoprostenol on effective pulmonary blood flow in normal volunteers.

A Bush1, C M Busst, A Millar, N Syrett.   

Abstract

1. Epoprostenol (prostacyclin) has been widely used as a vasodilator, but its effects on cardiac output are controversial and the time course of its effects little studied. 2. We report its cardiovascular effects in doses of 5 and 10 ng kg-1 min-1 in six healthy volunteers. 3. Each of the two doses caused a mean 20% rise in effective pulmonary blood flow and a 15% rise in heart rate. These effects appeared to reach a maximum within 10 min of starting or increasing the rate of infusion, with no evidence of a rebound effect. 4. When the dose was reduced, heart rate and effective pulmonary blood flow appeared to reach a new steady state within 5 min of reducing or stopping the infusion. Only minor side-effects were encountered, and they were rapidly reversed on stopping the drug. 5. These results should be applied to the therapeutic use of epoprostenol as a vasodilator, particularly when titrating the optimum dose for a given individual.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282532      PMCID: PMC1386358          DOI: 10.1111/j.1365-2125.1988.tb03312.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The components of the alveolar-arterial oxygen tension difference in normal subjects and in patients with pneumonia and obstructive lung disease.

Authors:  F F Davidson; J B Glazier; J F Murray
Journal:  Am J Med       Date:  1972-06       Impact factor: 4.965

2.  A new method for measurement of cardiac output with nitrous oxide.

Authors:  B Ayotte; J Seymour; M B McIlroy
Journal:  J Appl Physiol       Date:  1970-06       Impact factor: 3.531

3.  Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?

Authors:  A Bush; C Busst; K Booth; W B Knight; E A Shinebourne
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

4.  Prostacyclin infusion in hypertension: acute hemodynamic and hormonal effects.

Authors:  M Chaignon; M L Ruffie; M Lucsko; J L Cuche; J Guedon; J O'Grady
Journal:  N Engl J Med       Date:  1982-08-26       Impact factor: 91.245

5.  Comparison of intravenous and inhaled terbutaline in the treatment of asthma.

Authors:  R J Pierce; C R Payne; S J Williams; D M Denison; T J Clark
Journal:  Chest       Date:  1981-05       Impact factor: 9.410

6.  Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.

Authors:  L J Rubin; B M Groves; J T Reeves; M Frosolono; F Handel; A E Cato
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

7.  Validation of a Doppler technique for beat-to-beat measurement of cardiac output.

Authors:  N Mehta; V I Iyawe; A R Cummin; S Bayley; K B Saunders; E D Bennett
Journal:  Clin Sci (Lond)       Date:  1985-10       Impact factor: 6.124

8.  The effect of intravenous epoprostenol (prostacyclin, PGI2) on cerebral blood flow and cardiac output in man.

Authors:  P J Cook; C G Maidment; P Dandona; R A Hutton; I M James
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  Haemodynamic changes induced by prostacyclin in man.

Authors:  J Szczeklik; A Szczeklik; R Nizankowski
Journal:  Br Heart J       Date:  1980-09

10.  Effects of intravenous infusion of prostacyclin (PGI2) in man.

Authors:  J O'Grady; S Warrington; M J Moti; S Bunting; R Flower; A S Fowle; E A Higgs; S Moncada
Journal:  Prostaglandins       Date:  1980-02
View more
  2 in total

1.  Effect of infused adenosine on cardiac output and systemic resistance in normal subjects.

Authors:  A Bush; C M Busst; B Clarke; P J Barnes
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers.

Authors:  C M Busst; A Bush
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.